Gongwin Biopharm Holdings Co., Ltd. (TPEX: 6617)

Gongwin Biopharm Holdings Balance Sheet

Financials in millions TWD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Sep 30, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Cash & Equivalents	815.02	273.59	671.51	454.12	707.23	189.7
Short-Term Investments	1,174	668.66	434.1	372.2	297.09	423.2
Trading Asset Securities	445.44	-	-	-	34.41	33.17
Cash & Short-Term Investments	2,434	942.25	1,106	826.33	1,039	646.07
Cash Growth	157.33%	-14.78%	33.80%	-20.45%	60.78%	-14.19%
Accounts Receivable	14.54	10.58	-	-	-	-
Other Receivables	24.23	4.52	4.25	0.06	0.21	0.28
Receivables	38.77	15.1	4.25	0.06	0.21	0.28
Inventory	7.96	11.93	0.21	-	-	-
Prepaid Expenses	15.5	11.36	11.11	-	-	-
Other Current Assets	0.06	138.42	215.88	93.74	21.34	9.82
Total Current Assets	2,496	1,119	1,337	920.12	1,060	656.17
Property, Plant & Equipment	327.32	118.32	245.05	246.76	136.97	111.4
Long-Term Investments	509.39	156.61	32.35	3.88	5.34	5.62
Other Intangible Assets	0.28	0.19	-	-	0.01	0.11
Other Long-Term Assets	120.45	121.17	7.47	1.12	1.42	1.42
Total Assets	3,454	1,515	1,622	1,172	1,204	774.72
Accounts Payable	0.64	0.29	-	-	-	-
Accrued Expenses	-	26.37	32.63	21.97	19.03	18.97
Short-Term Debt	100.98	75.02	134.55	113.06	29.28	20.73
Current Portion of Leases	2.81	2.12	5.01	1.99	4.7	2.85
Current Income Taxes Payable	15.77	15.13	15.44	15.2	-	-
Other Current Liabilities	43.12	7.44	3.62	2.54	2.66	5.66
Total Current Liabilities	163.33	126.36	191.26	154.75	55.66	48.2
Long-Term Leases	13.24	0.03	2.18	0.1	2.11	-
Long-Term Unearned Revenue	44.81	45.08	42.03	29.57	27.97	29.93
Other Long-Term Liabilities	42.98	32.06	13.24	0	-	-
Total Liabilities	264.36	203.53	248.7	184.43	85.75	78.13
Common Stock	1,275	1,133	1,131	1,099	1,093	1,031
Additional Paid-In Capital	-	1,644	1,634	1,061	1,045	556.41
Retained Earnings	-1,507	-1,441	-1,349	-1,094	-972.88	-879.81
Comprehensive Income & Other	3,466	-21.35	-24.77	-95.34	-71.36	-42.06
Total Common Equity	3,191	1,315	1,392	970.72	1,093	665.57
Minority Interest	-1.19	-3.68	-18.58	16.74	25.21	31.02
Shareholders' Equity	3,189	1,312	1,373	987.45	1,118	696.59
Total Liabilities & Equity	3,454	1,515	1,622	1,172	1,204	774.72
Total Debt	117.03	77.17	141.74	115.14	36.09	23.58
Net Cash (Debt)	2,317	865.08	963.87	711.19	1,003	622.49
Net Cash Growth	165.28%	-10.25%	35.53%	-29.07%	61.07%	-4.85%
Net Cash Per Share	19.68	7.64	8.67	6.49	9.60	6.04
Filing Date Shares Outstanding	122.36	113.34	113.09	109.92	109.27	103.1
Total Common Shares Outstanding	122.36	113.34	113.09	109.92	109.27	103.1
Working Capital	2,333	992.7	1,146	765.37	1,005	607.97
Book Value Per Share	26.07	11.61	12.31	8.83	10.00	6.46
Tangible Book Value	3,190	1,315	1,392	970.72	1,093	665.46
Tangible Book Value Per Share	26.07	11.61	12.31	8.83	10.00	6.45
Land	-	49.69	155	155	49.69	49.69
Buildings	-	52.95	69.59	69.23	53.22	35.61
Machinery	-	63.43	56.76	54.91	54.13	37.24
Construction In Progress	-	-	-	0.54	-	5.77
Leasehold Improvements	-	3.75	3.75	3.75	3.75	3.75

Source: S&P Capital IQ. Standard template. Financial Sources.